{
  "id": 9356703,
  "title": "Roivant reports Phase 2b lupus failure for an FcRn drug",
  "url": "https://urgent.news/2026/09/23/roivant-reports-phase-2b-lupus-failure-for-an-fcrn-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-23T14:49:59.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/roivant-reports-phase-2b-lupus-failure-for-an-fcrn-drug/"
  },
  "original_language": "en",
  "account": null,
  "summary": "One of Roivant’s leading autoimmune pipeline candidates failed a Phase 2b study in a form of lupus, the company said Wednesday morning. The program, known as IMVT-1402 or imeroprubart, did not improve symptoms by a ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Endpoints News",
        "title": "Roche kidney drug's Phase 3 win sets up path to accelerated approval",
        "url": "https://urgent.news/2026/09/23/roche-kidney-drugs-phase-3-win-sets-up-path-to-accelerated-approval",
        "published": "2026-09-23T10:18:53.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}